Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 7, Pages 3485-3507Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b00985
Keywords
-
Categories
Funding
- European Commission 7th Framework Programme FP7 HEALTH-2013-INNOVATION1 [602666]
- EC 7th Framework Programme [REGPOT-CT2013-316149-InnovaBalt]
Ask authors/readers for more resources
Human African trypanosomiasis is causing thousands of deaths every year in the rural areas of Africa. In this manuscript we describe the optimization of a family of phtalazinone derivatives. Phosphodiesterases have emerged as attractive molecular targets for a novel treatment for a variety of neglected parasitic diseases. Compound 1 resulted in being a potent TbrPDEB1 inhibitor with interesting activity against T. brucei in a phenotypic screen. Derivative 1 was studied in an acute in vivo mouse disease model but unfortunately showed no efficacy due to low metabolic stability. We report structural modifications to achieve compounds with an improved metabolic stability while maintaining high potency against TbrPDEB1 and T. brucei. Compound 14 presented a good microsomal stability in mouse and human microsomes and provides a good starting point for future efforts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available